The European Medicines Agency (EMA) has given PRIME designation to Global Blood Therapeutics’ (Nasdaq: GBT) sickle cell disease candidate GBT440.
The company’s share price jumped over 5% in trading in New York this morning.
Under the priority review scheme, the candidate will now be eligible for early and proactive EMA support to expedite the regulatory review process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze